Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 20 clinical trials
CRAFT: The NCT-PMO-1602 Phase II Trial

revealed genetic alterations in a substantial proportion of patients including (i) alterations that lead to aberrant activation of BRAF, ERBB2, ALK, and the PI3K-AKT and MAPK pathways and (ii) changes that

  • 0 views
  • 08 Apr, 2022
  • 1 location
A Study of BDTX-189, an Orally Available Allosteric ErbB Inhibitor, in Patients With Advanced Solid Tumors. (MasterKey-01)

2 (HER2/ErbB2) genes or epidermal growth factor receptor (EGFR/ErbB1). The main goals of this study are to: Find the recommended dose of BDTX-189 that can be given safely to

solid tumor
growth factor
epidermal growth factor receptor
cancer treatment
EGFR
  • 10 views
  • 11 Mar, 2022
  • 25 locations
Radiotherapy Omission in Low Risk Ductal in Situ Carcinoma Breast (ROMANCE)

suggested that low proliferation, hormone receptors expression, and lack of ERBB2 amplification were associated with a low risk of IBR in patients not receiving radiotherapy. A combined signature was tested

epidermal growth factor receptor
cish
breast irradiation
cancer
chromogenic in situ hybridization
  • 51 views
  • 09 Feb, 2022
  • 27 locations
Targeting EGFR/ERBB2 With Neratinib in Hormone Receptor (HR)-Positive/HER2-negative HER2-enriched Advanced/Metastatic Breast Cancer

HR+/HER2-negative BC represent 70% of all newly diagnosed breast tumours and are responsible for most recurrences and deaths due to this disease, and despite available standard therapies, 15-20% of hormone tumours recur at distant sites. As BC is a clinically and biologically heterogeneous disease, intrincsic subtype may play an important …

endocrine therapy
her2/neu-negative breast cancer
core needle biopsy
mammogram
estrogen receptor
  • 0 views
  • 02 Aug, 2021
  • 15 locations
Omission of Surgery in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti-HER2-based Neoadjuvant Therapy (ELPIS)

This is a prospective, single arm, open-label, unicenter, exploratory study in women with primary operable HER2-positive, HER2-enriched/ERBB2-high breast cancer according to PAM50 intrinsic

  • 0 views
  • 21 Mar, 2022
  • 1 location
A Study of H3B-6545 in Combination With Palbociclib in Women With Advanced or Metastatic Estrogen Receptor-Positive Human Epidermal Growth Factor Receptor-2 (HER2)-Negative Breast Cancer

The primary objective of this study is to evaluate the safety and tolerability of H3B-6545 and palbociclib when administered in combination in order to determine the maximum tolerated dose (MTD) and/or the recommended Phase 2 dose (RP2D) of this combination in women with advanced or metastatic estrogen receptor-positive (ER+) HER2- …

epidermal growth factor receptor
stage iv breast cancer
breast cancer
palbociclib
EGFR
  • 29 views
  • 10 Nov, 2021
  • 12 locations
Poziotinib in EGFR Exon 20 Mutant Advanced NSCLC

This phase II trial studies how well poziotinib works in treating patients with non-small lung cancer with an EGFR or HER2 exon 20 mutation that is stage IV or has come back (recurrent). Poziotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell …

liver metastasis
neutrophil count
cancer
tumor cells
lung cancer
  • 1904 views
  • 28 Jan, 2022
  • 1 location
Assessing the Immunogenicity of pING-hHER3FL

receptor (HER) family including: HER1 (also known as EGFR), HER2, HER3 and HER4 (also known as ErbB2, ErbB3, and ErbB4 respectively) is an important receptor family for the development of many malignancies

solid tumor
liver metastasis
metastasis
hormone therapy
EGFR
  • 0 views
  • 12 May, 2022
  • 1 location
Personalized Targeted IMMUNOtherapy-based Regimens in Recurrent GASTric Adenocarcinoma (IMMUNOGAST)

> Tumor positive for Epstein-Barr virus (EBV) (8%), which display recurrent PIK3CA mutations, extreme DNA hypermethylation, and amplification of JAK2, ErbB2, PD-L1 and PD-L2;

  • 0 views
  • 06 Apr, 2021
  • 8 locations
Neratinib and Everolimus, Palbociclib, or Trametinib in Treating Participants With Refractory and Advanced or Metastatic Solid Tumors With EGFR Mutation/Amplification, HER2 Mutation/Amplification, or HER3/4 Mutation or KRAS Mutation

This phase I trial studies the side effects and best dose of neratinib in combination with everolimus, palbociclib, or trametinib in participants with solid tumors with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation, or KRAS mutation that do not respond to treatment (refractory) and have spread to other parts of the …

immunohistochemistry
epidermal growth factor receptor
liver metastasis
neutrophil count
somatic mutation
  • 36 views
  • 31 Jan, 2022
  • 1 location